MEDICINA
Departamento
University of Florence
Florencia, ItaliaPublicaciones en colaboración con investigadores/as de University of Florence (20)
2024
-
CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)
Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25
-
Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology
PLoS Computational Biology, Vol. 20, Núm. 2
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, Vol. 403, Núm. 10423, pp. 249-260
2023
-
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Blood
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
The Lancet, Vol. 401, Núm. 10373, pp. 269-280
2022
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Leukemia, Vol. 36, Núm. 5, pp. 1432-1435
-
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
Blood
2021
-
Imetelstat achieves meaningful and durable transfusion independence in high transfusion–Burden patients with lower-risk myelodysplastic syndromes in a phase II study
Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 48-56
-
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 13, pp. 1426-1436
2020
-
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
Leukemia Research
2019
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973
2018
-
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR
Haematologica, Vol. 103, Núm. 12, pp. 2079-2087
-
Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density
Annals of the rheumatic diseases, Vol. 77, Núm. 3, pp. 378-385
2017
-
Genetics of vascular dementia - review from the ICVD working group
BMC Medicine, Vol. 15, Núm. 1
-
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents
Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597
2013
-
Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease
Journal of Bone and Mineral Research, Vol. 28, Núm. 11, pp. 2338-2346
2011
2005
-
Imatinib is not a potential alternative treatment for uterine leiomyosarcoma (multiple letters)
Clinical Cancer Research